Outlook Therapeutics Inc OTLK.OQ OTLK.O is expected to show no change in quarterly revenue when it reports results on December 20 (estimated) for the period ending September 30 2024
LSEG's mean analyst estimate for Outlook Therapeutics Inc is for a loss of 83 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Outlook Therapeutics Inc is $33.00, above its last closing price of $1.44.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | -1.02 | -1.00 | -0.83 | Beat | 16.8 |
Mar. 31 2024 | -0.96 | -0.85 | -1.55 | Missed | -82.4 |
Dec. 31 2023 | -0.92 | -1.00 | -0.80 | Beat | 20 |
Sep. 30 2023 | -1.16 | -1.17 | -1.00 | Beat | 14.9 |
Jun. 30 2023 | -0.82 | -1.03 | -1.60 | Missed | -55.6 |
Mar. 31 2023 | -1.19 | -1.30 | -0.60 | Beat | 53.8 |
Dec. 31 2022 | -1.00 | -1.05 | -1.60 | Missed | -52.4 |
Sep. 30 2022 | -1.14 | -1.35 | -1.30 | Beat | 3.7 |
This summary was machine generated December 18 at 13:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments